MUC1/X Protein Immunization Enhances cDNA Immunization in Generating Anti-MUC1 α/β Junction Antibodies that Target Malignant Cells
Open Access
- 1 December 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (23), 11247-11253
- https://doi.org/10.1158/0008-5472.can-06-1486
Abstract
MUC1 has generated considerable interest as a tumor marker and potential target for tumor killing. To date, most antibodies against MUC1 recognize epitopes within the highly immunogenic α chain tandem repeat array. A major shortcoming of such antibodies is that the MUC1 α chain is shed into the peripheral circulation, sequesters circulating antitandem repeat array antibodies, and limits their ability to even reach targeted MUC1-expressing cells. Antibodies recognizing MUC1 epitopes tethered to the cell surface would likely be more effective. MUC1 α subunit binding the membrane-tethered β subunit provides such an epitope. By use of a novel protocol entailing immunization with cDNA encoding full-length MUC1 (MUC1/TM) followed by boosting with the alternatively spliced MUC1/X isoform from which the tandem repeat array has been deleted, we generated monoclonal antibodies, designated DMC209, which specifically bind the MUC1 α/β junction. DMC209 is exquisitely unique for this site; amino acid mutations, which abrogate MUC1 cleavage, also abrogate DMC209 binding. Additionally, DMC209 specifically binds the MUC1 α/β junction on full-length MUC1/TM expressed by breast and ovarian cancer cell lines and on freshly obtained, unmanipulated MUC1-positive malignant plasma cells of multiple myeloma. DMC209 is likely to have clinical application by targeting MUC1-expressing cells directly and as an immunotoxin conjugate. Moreover, the novel immunization procedure used in generating DMC209 can be used to generate additional anti-MUC1 α/β junction antibodies, which may, analogously to Herceptin, have cytotoxic activity. Lastly, sequential immunization with MUC1/TM cDNA acting as a nonspecific adjuvant followed by protein of interest may prove to be a generalizable method to yield high-titer specific antibodies. (Cancer Res 2006; 66(23): 11247-53)Keywords
This publication has 40 references indexed in Scilit:
- Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucinNature Structural & Molecular Biology, 2005
- Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunityAnnals Of Oncology, 2004
- MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cellsJournal of Leukocyte Biology, 2004
- MUC1 expression in human prostate cancer cell lines and primary tumorsProstate Cancer and Prostatic Diseases, 2004
- Identification of MUC1 Proteolytic Cleavage Sites in VivoBiochemical and Biophysical Research Communications, 2001
- Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patientsInternational Journal of Cancer, 2001
- Review Article The immunology and immunotherapy of breast cancer: an updateInternational Journal of Immunopharmacology, 1999
- Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating functionInternational Journal of Cancer, 1997
- A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1British Journal of Haematology, 1996
- Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins Cytokine receptor‐like moleculesFEBS Letters, 1994